TrialGynecologic oncology2023

A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.

Roisin E O'Cearbhaill et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.